To access this element change to forms mode OFF
Grant Award View - GA22381
Development of a novel PDL2-based immune therapy for cancer
GA ID:
GA22381
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
16-Jul-2018
Publish Date:
2-Oct-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2021
Value (AUD):
$583,765.10
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
Development of a novel PDL2-based immune therapy for cancer
Purpose:
Immuno-modulators utilise the patient’s own immune system to eliminate or slow the growth of cancer. Current therapies target a single molecule. This development grant would allow us to work towards developing novel treatment for cancer which targets two molecules at the same time.
GO ID:
GO Title:
Development Grants
Internal Reference ID:
GNT1155161
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
QIMR Berghofer Medical Research Institute
Recipient ABN:
31 411 813 344
Grant Recipient Location
Suburb:
Herston
Town/City:
Herston
Postcode:
4006
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, UNITED STATES